Loading...

We've got a brand new version of Simply Wall St! Try it out

MPX International

CNSX:MPXI
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MPXI
CNSX
CA$60M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

MPX International Corporation, a cannabis company, focuses on the medical and adult-use cannabis markets. The last earnings update was 227 days ago. More info.


Add to Portfolio Compare Print
  • MPX International has significant price volatility in the past 3 months.
MPXI Share Price and Events
7 Day Returns
-7.3%
CNSX:MPXI
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:MPXI
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
MPXI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MPX International (MPXI) -7.3% 3.5% -11% - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on MPXI.
  • No trading data on MPXI.
Price Volatility
Industry
5yr Volatility vs Market

MPXI Value

 Is MPX International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether MPX International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MPX International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MPX International. This is due to cash flow or dividend data being unavailable. The share price is CA$0.445.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MPX International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MPX International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:MPXI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD Not available
CNSX:MPXI Share Price ** CNSX (2019-09-19) in CAD CA$0.45
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MPX International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for MPX International, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does MPX International's expected growth come at a high price?
Raw Data
CNSX:MPXI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MPX International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MPX International's assets?
Raw Data
CNSX:MPXI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD Not available
CNSX:MPXI Share Price * CNSX (2019-09-19) in CAD CA$0.45
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x

* Primary Listing of MPX International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine MPX International's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MPX International's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess MPX International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. MPX International has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MPXI Future Performance

 How is MPX International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MPX International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MPX International expected to grow at an attractive rate?
  • Unable to compare MPX International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MPX International's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare MPX International's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:MPXI Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:MPXI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (11 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:MPXI Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -1 -2
2018-06-30 0 -1 -1
2018-03-31 0 -1 -1
2017-03-31 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MPX International is high growth as no earnings estimate data is available.
  • Unable to determine if MPX International is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:MPXI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (11 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from MPX International Company Filings, last reported 11 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MPXI Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30
2018-06-30
2018-03-31
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MPX International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine MPX International's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. MPX International's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. MPX International's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess MPX International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MPX International has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MPXI Past Performance

  How has MPX International performed over the past 5 years?

  • MPX International's last earnings update was 227 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MPX International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MPX International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare MPX International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MPX International's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
MPX International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MPX International Company Filings, last reported 11 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MPXI Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.07 -1.93 1.33
2018-06-30 0.04 -1.35 1.05
2018-03-31 0.01 -0.77 0.76
2017-03-31 -0.89 0.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MPX International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MPX International has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MPX International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MPX International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MPX International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MPXI Health

 How is MPX International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MPX International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MPX International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MPX International's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MPX International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • MPX International has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MPX International Company Filings, last reported 11 months ago.

CNSX:MPXI Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 26.12 0.00 0.16
2018-06-30 -0.68 0.00
2018-03-31 -0.68 0.00
2017-03-31 -1.00 0.00 0.06
  • MPX International has no debt.
  • MPX International has not taken on any debt in the past 5 years.
  • MPX International has no debt, it does not need to be covered by operating cash flow.
  • MPX International has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess MPX International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MPX International has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MPXI Dividends

 What is MPX International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MPX International dividends.
If you bought CA$2,000 of MPX International shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MPX International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MPX International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:MPXI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MPX International has not reported any payouts.
  • Unable to verify if MPX International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MPX International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MPX International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MPX International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MPX International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MPX International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MPXI Management

 What is the CEO of MPX International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
W. Boyes
AGE 68
CEO Bio

Mr. W. Scott Boyes has been a Consultant for NCD Associates since 2009. Mr. Boyes served as the Chief Financial Officer, Treasurer, and Secretary at GroveWare Technologies Ltd. until January 22, 2013. He has been Chairman at MPX Bioceutical Corporation since October 30, 2017, CEO since January 2015, President since January 2015 and Director since November 18, 2014. He is the Chairman, President & CEO at MPX International Corporation. Mr. Boyes focused his consulting services on financial restructuring, revenue enhancement and streamlining business processes for distressed or high growth companies at NCD Associates. He served as the Chief Financial Officer, Treasurer and Secretary at ePhoto Image, Inc. since April 6, 2012. Mr. Boyes is a seasoned Senior Executive with diversified and cross-functional experience, combining MBA credentials with a strong career background in revenue development and general management. Mr. Boyes has extensive management, business and executive experience. He served as the Chief Financial Officer, Principal Accounting Officer, Secretary and Treasurer at Great Wall Builders Ltd. until September 23, 2011. In 2005, Mr. Boyes founded and developed Railcrew Xpress Corporation and served as its President and Chief Executive Officer until 2008. He developed and led the sales and customer service teams, managed the acquisition and integration of three competitor companies and developed and deployed sophisticated dispatch, tracking and reporting technology. From 2000 to 2005, Mr. Boyes served as President and Chief Executive Officer of Hallcon Corporation, where he was responsible for its senior executive management and its operating subsidiaries. Previously, he served as a Vice President a large Canadian Bank and Vice President and General Manager of a business unit within a multinational commercial finance company. He served as Director of GroveWare Technologies Ltd. until January 22, 2013. He served as a Director at ePhoto Image, Inc. since April 6, 2012. He served as a Director at Great Wall Builders Ltd. until September 23, 2011. He holds MBA credentials.

CEO Compensation
  • Insufficient data for W. to compare compensation growth.
  • Insufficient data for W. to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

W. Boyes

TITLE
Chairman
AGE
68

David McLaren

TITLE
Chief Financial Officer
AGE
48

Jonathan Chu

TITLE
Vice President of Finance & Accounting

Jeremy Budd

TITLE
Executive VP
AGE
40

Michael Arnkvarn

TITLE
Chief Operating Officer of Canada
Board of Directors

W. Boyes

TITLE
Chairman
AGE
68

Jeremy Budd

TITLE
Executive VP
AGE
40

Charles Akle

TITLE
Member of Medical Advisory Board
TENURE
0.3 yrs

Alastair Crawford

TITLE
Director

Robert Petch

TITLE
Director

Randy Stafford

TITLE
Director

Damian West

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
25. Mar 19 Buy Nancy McLaren Individual 21. Mar 19 21. Mar 19 280,375 CA$0.48 CA$134,580
25. Mar 19 Buy Randall Stafford Individual 21. Mar 19 21. Mar 19 687,500 CA$0.48 CA$330,000
25. Mar 19 Buy W. Boyes Individual 21. Mar 19 21. Mar 19 2,806,250 CA$0.48 CA$1,347,001
25. Mar 19 Buy Alastair Crawford Individual 21. Mar 19 21. Mar 19 6,950,593 CA$0.48 CA$3,336,287
25. Mar 19 Buy Jeremy Budd Individual 21. Mar 19 21. Mar 19 440,957 CA$0.48 CA$211,659
25. Mar 19 Buy David McLaren Individual 21. Mar 19 21. Mar 19 280,375 CA$0.48 CA$134,580
X
Management checks
We assess MPX International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MPX International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MPXI News

Simply Wall St News

MPXI Company Info

Description

MPX International Corporation, a cannabis company, focuses on the medical and adult-use cannabis markets. It focuses on producing and distributing three principal types of products, such as cannabis flowers, and cannabis oil concentrates and related products, as well as cannabis derivatives under the brand name of MPX. The company was incorporated in 2018 and is headquartered in Toronto, Canada.

Details
Name: MPX International Corporation
MPXI
Exchange: CNSX
Founded: 2018
CA$60,139,296
135,144,487
Website: http://mpxinternationalcorp.com
Address: MPX International Corporation
5255 Yonge Street,
Suite 701,
Toronto,
Ontario, M2N 6P4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MPXI Common Shares Canadian National Stock Exchange CA CAD 04. Feb 2019
OTCPK MPXO.F Common Shares Pink Sheets LLC US USD 04. Feb 2019
MUN 2J6 Common Shares Boerse Muenchen DE EUR 04. Feb 2019
BST 2J6 Common Shares Boerse-Stuttgart DE EUR 04. Feb 2019
Number of employees
Current staff
Staff numbers
0
MPX International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:27
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/02/05
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.